GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » YoY EPS Growth

Amryt Pharma (Amryt Pharma) YoY EPS Growth : 14.29% (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Amryt Pharma's YoY EPS Growth for the quarter that ended in Sep. 2022 was 14.29%.

Amryt Pharma's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.30.


Amryt Pharma YoY EPS Growth Historical Data

The historical data trend for Amryt Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma YoY EPS Growth Chart

Amryt Pharma Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -179.71 21.10 -24.70 20.48 100.61

Amryt Pharma Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 125.00 44.44 50.00 14.29

Amryt Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Amryt Pharma's YoY EPS Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY EPS Growth (A: Dec. 2021 )
=(Earnings per Share (Diluted) (A: Dec. 2021 )-Earnings per Share (Diluted) (A: Dec. 2020 ))/ | Earnings per Share (Diluted) (A: Dec. 2020 ) |
=(0.02--3.3)/ | -3.3 |
=100.61 %

Amryt Pharma's YoY EPS Growth for the quarter that ended in Sep. 2022 is calculated as:

YoY EPS Growth (Q: Sep. 2022 )
=(Earnings per Share (Diluted) (Q: Sep. 2022 )-Earnings per Share (Diluted) (Q: Sep. 2021 )) / | Earnings per Share (Diluted) (Q: Sep. 2021 )) |
=(-0.3--0.35)/ | -0.35 |
=14.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amryt Pharma YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Amryt Pharma (Amryt Pharma) Business Description

Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

Amryt Pharma (Amryt Pharma) Headlines